A Single-Arm Trial to Evaluate Tocilizumab (IL-6 Receptor Antibody) in Chinese COVID-19 Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

20 Mar 2020 New trial record
16 Mar 2020 According to a Regeneron Pharmaceuticals media release, interleukin-6 (IL-6) may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or critically ill with COVID-19.The role of IL-6 is supported by preliminary data from this single-arm study in China.Based on these preliminary data, China recently updated its COVID-19 treatment guidelines and approved the use of that IL-6 inhibitor to treat patients with severe or critical disease.
16 Mar 2020 Preliminary data (initial non-peer reviewed results) from this trial presented in a Regeneron Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com